在充满挑战的市场环境中，IRD股票已触及52周低点，交易价格为1.07美元。这一价格水平反映了该公司面临的巨大压力，因为投资者对行业面临的各种不利因素做出了反应。在过去一年里，在BATS上市的Rexahn Pharmaceuticals Inc股价大幅下跌，一年来的变化显示下降了66. ...

"（加税步伐）越快启动越好，但现政府的政策倾向就像是在路上踢易拉罐--只是把问题往后拖。那些较为年长的、富裕的婴儿潮一代和Gen X一代人是最有可能承担加税成本的群体，因为这部分人拥有相应的财富，但是他们很可能会反对改变。" ...

Inland Revenue is cracking down on outstanding student loans - and has doubled its team working on overseas collections.

周三，H.C. Wainwright更新了对Opus Genetics (NASDAQ:IRD)股票的评级，给予"买入"评级，目标价为$8.00。该公司分析师指出了公司遗传性视网膜疾病 (IRD)平台的潜力，该平台包括针对Leber先天性黑矇 (LCA)、Best黄斑营养不良 (BEST1)和视网膜色素变性 (RP)的治疗方案。

IRD在今年6月发布的绩效改进报告中表示，税务局将致力于评估并报告估算的成本和收益，并报告"税收缺口"--税收缺口指纳税人或企业在应该纳税时却未纳税的情况。

根据AI大模型测算威孚高科后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，下方累积一定获利筹码。近期该股获筹码青睐，且集中度渐增。舆情分析来看，1家机构预测目标均价21.00，高于当前价15.77%。目前市场情绪悲观。

Well, here’s some good news if you don't like the idea of people freeloading on other taxpayers - the IRD has finally started ...

Inland Revenue (IRD) has put a full stop to sharing taxpayers’ details with social media platforms for marketing. It follows ...

Fi, LAN and internet connectivity to service its 20 nationwide sites and 4,100 staff in a deal that could last up to a decade ...

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of 3.33% and 230.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

"Since we became aware of IRD using taxpayer information to run targeted social media campaigns, New Zealanders have been ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research ...